Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
15–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
histologically or cytologically proven diagnosis of malignancy other than NSCLC
positive for translocation or inversion event involving the ALK gene locus
positive for ALK amplification events
positive for ALK activating point mutations
You may not be if
mutations of amplifications involving the c-Met gene but not the ALK gene
concurrent treatment on another therapeutic clinical trial
prior therapy specifically directed against ALK
Clareo Health | Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)
